PARSIPPANY, N.J. and
INDIANAPOLIS, April 28, 2015 /PRNewswire/ -- People with
acute coronary syndrome (ACS) who undergo an angioplasty procedure
and receive a heart stent are prescribed an oral antiplatelet (OAP)
therapy and aspirin to help prevent a heart attack, a blood clot in
their heart stent (stent thrombosis), or even death.[3] Yet, a
recent survey conducted by Harris Poll found that 52 percent of 275
ACS patients who were currently taking an OAP have missed taking or
changed the way they take their prescribed OAP therapy, even though
most of them were informed by their doctors of the importance of
the therapy to their heart health.[4] Of these respondents, those
under age 65 (194 participants) were much more likely not to follow
their OAP therapy regimen as prescribed than older respondents,
even though they were more concerned about their health, according
to the survey findings.[4]
To address this critical issue, the Preventive Cardiovascular
Nurses Association (PCNA), Society for Cardiovascular Angiography
and Interventions (SCAI) and Mended Hearts, with support from
Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY), urge
health care professionals to increase their efforts to help ACS
patients stick to their prescribed OAP therapy following an
angioplasty or cardiac stent procedure. As the survey found: 12
percent of the total survey respondents said they do not recall
being informed by their health care professionals that they faced
serious health risks if they did not adhere to their OAP
therapy.[4]
"For people who have recently received a heart stent for ACS,
changing, skipping or discontinuing OAP therapy increases the risk
of serious heart problems or even death," said Jeffrey Cavendish MD, FSCAI, FACC, lead
interventional cardiologist for Kaiser Permanente San Diego and
director of the cardiac catheterization laboratory at the Scripps
Prebys Cardiovascular Institute in La
Jolla, California.
To help ACS patients prevent recurrent heart events after an
angioplasty procedure, SCAI, PCNA and Mended Hearts are introducing
the "After the Stent: Follow Your Action PlanTM"
campaign. The campaign aims to mobilize cardiovascular health care
professionals to improve ACS patients' knowledge and practices
related to OAP adherence.
Annually, about 610,000 people with ACS, which includes heart
attack and a type of chest pain called unstable angina (UA),
undergo an angioplasty procedure to open a blocked coronary
artery.[5][6][7] Clinical research shows that up to 16 percent of
these patients stop taking their prescribed OAP therapy in the
first 30 days,[1][8] which leaves them more vulnerable to another
heart event and increases by 10-fold their risk of death at one
year.[1]
"Patients may stop taking their OAP medication for a variety of
reasons, such as mistakenly believing their heart condition is
'fixed' or not understanding why or how long they need to take the
medication," said Lola Coke, PHD,
ACNS-BC, RN-BC, FAHA, FPCNA, associate professor of nursing and
cardiovascular clinical nurse specialist at Rush University Medical Center in Chicago, Illinois, and member of the board of
directors of PCNA. "Identifying and correcting these
misunderstandings is a first step health care professionals can
take to ensure medication adherence. Health care professionals need
to make sure that ACS patients and caregivers have the right
information and support to follow their medication regimens."
To launch the "After the Stent: Follow Your Action
PlanTM" campaign, PCNA and SCAI published a position
paper that demonstrates the need for increased attention to OAP
medication and highlights practical, research-based solutions to
address nonadherence through education, mobilization,
personalization and teamwork. The paper can be viewed at
http://www.healio.com/cardiology/education-lab/2015/04_april/spotlight/spotlight.
Additionally, the groups have developed an OAP nonadherence risk
Assessment for health care professionals to use with their
patients. The Assessment includes the 8-question Morisky Medication
Adherence Screener, widely used in other disease categories to
assess medication adherence,[9][10][11][12] six questions specific
to ACS patients who have undergone an angioplasty procedure, and a
Conversation Guide to help health care professionals tailor
conversations with individual patients based on the risk factors
identified in the Assessment questionnaires.
Survey Reveals Education and Support Gap, Particularly for
Younger Patients4
The survey also
found that of the 296 respondents who visited a health care
professional within the 12 months following their angioplasty
procedure, 20 percent said they had questions about their
prescribed OAP medication that were not addressed by their health
care team. Most likely to have questions were those under age 65
(209 participants). Additionally, those under age 65 were less
aware than those 65 years or older that not taking their OAP
medication as prescribed could lead to future cardiac events (74
percent vs 88 percent of total respondents respectively)*.
Moreover, only 54 percent of the total respondents overall said
they remember being asked during a follow-up visit with their
physician if they filled their OAP medication prescription.
"Coping with a heart event is an overwhelming experience for
patients and their families, which makes it especially important
that health care professionals take the time to explain what
occurred and what needs to happen after the angioplasty procedure
to help prevent another heart event," said Donnette Smith, executive vice president of
Mended Hearts. "It is also equally important that patients and
caregivers ask their health care team questions if they have
concerns or are not clear why or how they should follow their new
medication regimen. There are excellent support programs and tools
available to help patients to successfully manage their OAP
medication routine. We encourage ACS patients and caregivers to ask
for help and support resources."
About Acute Coronary Syndrome (ACS)
ACS, which
includes heart attack and a type of chest pain called unstable
angina (UA), was responsible for the hospitalization of more than
one million people in the United
States in 2010.[5] The annual incidence of new heart
attacks is estimated to be approximately 620,000 and about 295,000
people will have a recurrent attack.[5] There are two main
types of heart attack: non-ST-segment elevation, or NSTEMI, and
ST-segment elevation, or STEMI. STEMI heart attacks are often
considered more severe as the artery is often fully blocked,
preventing blood flow to the heart.
Each year, approximately 610,000 people undergo PCI, which
typically includes the implantation of a stent that restores blood
flow to blocked arteries in the heart.[5][6][7] The number of UA or
NSTEMI ACS patients worldwide who are managed without acute
coronary interventions, such as PCI, has ranged from 32 percent to
almost 60 percent over the last few years.[13][14]
ACS may result in heart attack, stroke and death, costing
Americans more than $150 billion each
year.[15] Nearly 60 percent of the U.S healthcare costs of ACS are
due to re-hospitalization.[15] Strategies to prevent recurrent
heart attacks and re-hospitalization are important to improve
patient outcomes and reduce the cost burden of ACS.
About the Survey
The survey was conducted
online by Harris Poll on behalf of Daiichi Sankyo, Inc. and Eli
Lilly and Company from February 13 - April 10, 2014 among 305
adults in the Unites States between the ages of 35 to 74 who
underwent an angioplasty procedure with or without a stent within a
year of participating in the survey and were prescribed an OAP
medication. At the time of the survey, 214 participants were under
65 years old and 91 were 65 years old or older. Of the total
participants, 275 were currently using a prescribed OAP medication
and 30 had discontinued their prescribed OAP therapy before a year.
For a full methodology, please contact Tim
Coulom at tim.coulom@lilly.com.
About PCNA
The Preventive Cardiovascular Nurses Association (PCNA) is the
leading nursing organization dedicated to preventing cardiovascular
disease (CVD) through assessing risk, facilitating lifestyle
changes, and guiding individuals to achieve treatment goals. The
mission of PCNA is to promote nurses as leaders in the prevention
and management of cardiovascular disease. PCNA does this by
educating and supporting nurses through the development of
professional and patient education, leadership, and advocacy. For
more information call 1-608-250-2440 or
visit www.pcna.net.
About SCAI
The Society for Cardiovascular Angiography
and Interventions is a 4,200-member professional organization
representing invasive and interventional cardiologists in
approximately 70 nations. SCAI's mission is to promote excellence
in invasive/interventional cardiovascular medicine through
physician education and representation, and advancement of quality
standards to enhance patient care. SCAI's public education program,
Seconds Count, offers comprehensive information about
cardiovascular disease. For more information about SCAI and Seconds
Count, visit http://www.SCAI.org/ or www.SecondsCount.org. Follow
@SCAI and @SCAINews on Twitter for the latest heart health
news.
About Mended Hearts
Mended Hearts is the largest
heart patient support network in the world. 20,000 members operate
through 300 chapters across the U.S. Recognized for its role in
facilitating a positive patient-care experience, Mended Hearts
partners with 460 hospitals and rehabilitation clinics and offers
services to heart patients through visiting programs, support group
meetings and educational forums. The Mended Hearts is dedicated to
inspiring hope in heart disease patients and their families.
About Daiichi Sankyo
The Daiichi Sankyo Group is
dedicated to the creation and supply of innovative pharmaceutical
products to address the diversified, unmet medical needs of
patients in both mature and emerging markets. While maintaining its
portfolio of marketed pharmaceuticals for hypertension,
hyperlipidemia, and bacterial infections, the Group is engaged in
the development of treatments for thrombotic disorders and focused
on the discovery of novel oncology and cardiovascular-metabolic
therapies. Furthermore, the Daiichi Sankyo Group has created a
"Hybrid Business Model," which will respond to market and customer
diversity and optimize growth opportunities across the value chain.
For more information, please visit www.daiichisankyo.com. Daiichi
Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the
Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc.,
please visit www.dsi.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com, @LillyHealth on
Twitter and newsroom.lilly.com/social-channels.
P-LLY
Media Contacts:
Tim
Coulom
Eli Lilly and Company
317-771-2241
Tim.coulom@lilly.com
Julie Piszczor
Weber Shandwick
312-988-2094
JPiszczor@webershandwick.com
Jenn McGuire
Sr. Manager, Product Public Relations
Daiichi Sankyo, Inc.
973-944-2160
jmcguire@dsi.com
After the Stent: Follow Your Action PlanTM is a
trademark of Eli Lilly and Company.
©Daiichi Sankyo, Inc. and Lilly USA, LLC 2/2015. All Rights Reserved.
PG92367.
*Finding is directional in nature as 65+ sample is <100.
[1] Spertus JA, Kettelkamp R, Vance C, et al. Prevalence,
predictors, and outcomes of premature discontinuation of
thienopyridine therapy after drug-eluting stent placement: results
from the PREMIER registry. Circulation.
2006;113:2803–2809.
[2] Rothberg MB, Sivalingam SK, Ashraf J, et al. Patients' and
Cardiologists' Perceptions of the Benefits of Percutaneous Coronary
Intervention for Stable Coronary Disease. Ann Intern Med.
2010;153:307-313.
[3] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI
Guideline for Percutaneous Coronary Intervention: Executive
Summary: A Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines and the Society for Cardiovascular Angiography and
Interventions. Circulation. 2011;124:2574-2609.
[4]Study conducted online by Harris Poll on behalf of Daiichi
Sankyo, Inc. and Eli Lilly and Company from February 13 – April 10,
2014 among 305 respondents in the US. Qualifying respondents
were between the ages of 35-74, had an angioplasty procedure in the
previous 12 months and were prescribed oral antiplatelet
therapy.
[5] Go AS, Mozaffarian D, Roger VL, et al. for the American Heart
Association Statistics Committee and Stroke Statistics
Subcommittee. Heart disease and stroke statistics – 2014 update.
Circulation. Published online December 18, 2013.
[6] Gibson CM, Pride YB, Frederick PD, et al. Trends in Reperfusion
Strategies, Door-to-Needle and Door-to-Balloon Times, and
In-Hospital Mortality Among Patients with ST-Segment Elevation
Myocardial Infarction Enrolled in the National Registry of
Myocardial Infarction from 1990 to 2006. American Heart
Journal. 2008;156:1035-44.
[7] Roe MT, Chen AY, Cannon CP, et al. Temporal Changes in the Use
of Drug-Eluting Stents for Patients with Non–ST-Segment–Elevation
Myocardial Infarction Undergoing Percutaneous Coronary Intervention
from 2006 to 2008. Circulation: Cardiovascular Quality
Outcomes. 2009;2:414-420.
[8] Quadros A, Welter D, Camozzatto F. Identifying Patients at Risk
for Premature Discontinuation of Thienopyridine After Coronary
Stent Implantation. American Journal of Cardiology
2011;107(5):685-9.
[9] Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive Validity
of a Medication Adherence Measure for Hypertension Control.
Journal of Clinical Hypertension. 2008;10(5):348-354.
[10] Trindade AJ, Ehrlich A, Kornbluth A, Ullman T. Are Your
Patients Taking Their Medicine? Validation of a New Adherence Scale
in Patients with Inflammatory Bowel Disease and Comparison with
Physician Perception of Adherence. Inflamm Bowel Dis.
2011;17:599-604.
[11] Reynolds K, Viswanathan HN, O'Malley CD, et al. Psychometric
Properties of the Osteoporosis-Specific Morisky Medication
Adherence Scale in Postmenopausal Women with Osteoporosis Newly
Treated with Bisphosphonate. Ann Pharmacother. May 2012;46(5):659-670.
[12] Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE,
Muntner P. New Medication Adherence Scale Versus Pharmacy Fill
Rates in Seniors with Hypertension. Am J Manag Care.
2009;15(1):59-66.
[13] Fox KAA, Steg PG, Eagle KA, et al. Decline in rates of death
and heart failure in acute coronary syndromes, 1999-2006. J Am
Med Assoc. 2007;297:1892-1900.
[14] Chan MY, Mahaffey KW, Sun LJ, et al. Prevalence, predictors,
and impact of conservative medical management for patients with
non-ST-segment elevation acute coronary syndromes who have
angiographically documented significant coronary disease. J Am
Coll Cardiol. 2008;1:369-378.
[15] Kolansky DM. Acute coronary syndromes: Morbidity, mortality
and pharmacoeconomic burden. Am J Manag Care.
2009;15:S36-S41.
Logo -
http://photos.prnewswire.com/prnh/20031219/LLYLOGO
Logo - http://photos.prnewswire.com/prnh/20120826/DE62850LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/survey-finds-half-of-heart-stent-patients-dont-take-their-oral-antiplatelet-medication-as-prescribed-300072536.html
SOURCE Eli Lilly and Company